PRESS RELEASE published on 01/22/2024 at 18:32, 1 year 10 months ago RJD Green Inc.'s Management Discusses 2023 Calendar Year-End Results and 2024 Growth Focus RJD Green Inc. CEO Ron Brewer updates shareholders on the 2023 calendar year-end results and targeted 2024 growth, discussing the company's operations in healthcare services, construction products, and environmental services. The update covers the latest developments, contracts, revenue projections, and expansion plans for the coming year, outlining the focus on acquiring and managing assets and companies. The press release also includes the company's financial snapshots for the 2023 and 2022 calendar years. RJD Green Inc. 2023 Calendar Year-end Results 2024 Growth Focus Acquiring And Managing Assets Financial Snapshots
Published on 12/18/2025 at 00:55, 2 hours 59 minutes ago Molten Metals Corp. Announces Flow-Through Financing
Published on 12/18/2025 at 00:00, 3 hours 54 minutes ago Right Season Investments Announces Name Change to FutureGen Industries Corp.
Published on 12/17/2025 at 23:15, 4 hours 39 minutes ago Northern Superior Announces the Ratio for the Distribution of the Common Shares in the Capital of ONGold Resources Ltd.
Published on 12/17/2025 at 15:00, 12 hours 54 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 13 hours 54 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/18/2025 at 01:10, 2 hours 44 minutes ago Samsung To Unveil New AI-Connected Living Lineup at CES 2026
Published on 12/18/2025 at 00:50, 3 hours 4 minutes ago Historic production of graphene enhanced cement successfully completed
Published on 12/17/2025 at 22:05, 5 hours 49 minutes ago Abivax annonce l’acceptation de 22 abstracts sur obefazimod dans les MICI à l’ECCO 2026, dont une présentation orale sur des résultats précliniques antifibrotiques
Published on 12/17/2025 at 22:05, 5 hours 49 minutes ago Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Published on 12/17/2025 at 21:22, 6 hours 32 minutes ago EQS-Adhoc: DATAGROUP SE: DATAGROUP SE Management Board plans dividend of EUR 0.04 per share
Published on 12/17/2025 at 20:39, 7 hours 15 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 20:39, 7 hours 15 minutes ago Aeroports de Paris SA | Tarifs des redevances aeroportuaires 2026 à Paris
Published on 12/17/2025 at 19:30, 8 hours 24 minutes ago Evolution de la composition du Conseil d’Administration
Published on 12/17/2025 at 18:00, 9 hours 54 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025